keyword
MENU ▼
Read by QxMD icon Read
search

PRRT

keyword
https://www.readbyqxmd.com/read/28428192/long-term-efficacy-survival-and-safety-of-177lu-dota0-tyr3-octreotate-in-patients-with-gastroenteropancreatic-and-bronchial-neuroendocrine-tumors
#1
Tessa Brabander, Wouter A Van der Zwan, Jaap Jm Teunissen, Boen L R Kam, Richard A Feelders, Wouter W de Herder, Casper H J van Eijck, Gaston J H Franssen, Eric P Krenning, Dik J Kwekkeboom
Purpose<br /> Bronchial and gastroenteropancreatic neuroendocrine tumors (NETs) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogs. We have treated over 1200 patients with peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE) since the year 2000 and present the results on efficacy, survival and toxicity of this therapy. <p>Patients and methods<br /> For safety analysis, 610 patients treated with a cumulative dose of at least 100 mCi (3...
April 20, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28400403/molecular-imaging-in-the-investigation-of-hypoglycaemic-syndromes-and-their-management
#2
David A Pattison, Rodney J Hicks
There has been recent progress in molecular imaging using a variety of cellular targets for the investigation of adult non-diabetic hypoglycaemic syndromes and its integration into patient management. These targets include peptide receptors - somatostatin receptors (SSTR) and glucagon-like peptide-1 receptor (GLP-1R) - the Amine Precursor Uptake and Decarboxylation system utilising the diphydroxyphenylaline (DOPA) analogue 6-[18F]-L-fluoro-L-3, 4-dihydroxyphenylalanine (18F-FDOPA), and glycolytic metabolism with 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)...
April 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28361189/personalized-177-lu-octreotate-peptide-receptor-radionuclide-therapy-of-neuroendocrine-tumours-a-simulation-study
#3
Michela Del Prete, François-Alexandre Buteau, Jean-Mathieu Beauregard
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with (177)Lu-octreotate is commonly administered at empiric, fixed amounts of injected radioactivity (IA). This results in highly variable absorbed doses to critical organs and suboptimal treatment of most patients. The primary aims of this study were to design a personalized PRRT (P-PRRT) protocol based on dosimetry, and to perform a simulation of this protocol in a retrospective cohort of patients with neuroendocrine tumours, in order to assess the potential of P-PRRT to safely increase the absorbed dose to the tumour during a four-cycle induction course...
March 31, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28331954/individualised-177-lu-dotatate-treatment-of-neuroendocrine-tumours-based-on-kidney-dosimetry
#4
Anna Sundlöv, Katarina Sjögreen-Gleisner, Johanna Svensson, Michael Ljungberg, Tomas Olsson, Peter Bernhardt, Jan Tennvall
PURPOSE: To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED). METHOD: Treatment was given with repeated cycles of 7.4 GBq (177)Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry was performed in all patients after each cycle using a hybrid method (SPECT + planar imaging)...
March 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28320783/pitfalls-in-the-response-evaluation-after-prrt-with-177-lu-dota-0-tyr-3-octreotate
#5
Tessa Brabander, Wouter Van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, R A Feelders, Eric P Krenning, Dik Kwekkeboom
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumour (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up...
March 20, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28319500/clinical-response-profile-of-metastatic-advanced-pulmonary-neuroendocrine-tumors-to-peptide-receptor-radionuclide-therapy-with-177lu-dotatate
#6
Rahul V Parghane, Sanjay Talole, Kumar Prabhash, Sandip Basu
OBJECTIVES: The aims of this study were to perform multiparametric response assessment of metastatic/advanced pulmonary neuroendocrine tumors (NETs) to Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) (clinical, biochemical, molecular/structural imaging, and survival assessment) and to study the relationship between response, mortality, and overall survival with dual-tracer molecular imaging parameters. METHODS: Twenty-two patients (6 women, 16 men; median age, 44 years; range, 16-72 years) of histopathologically proven pulmonary NETs with metastatic/advanced disease were included and analyzed retrospectively...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28316066/long-term-results-and-tolerability-of-tandem-peptide-receptor-radionuclide-therapy-with-90-y-177-lu-dotatate-in-neuroendocrine-tumors-with-respect-to-the-primary-location-a-10-year-study
#7
Jolanta Kunikowska, Dariusz Pawlak, Marianna I Bąk, Beata Kos-Kudła, Renata Mikołajczak, Leszek Królicki
INTRODUCTION: The peptide receptor radionuclide therapy (PRRT) with (90)Y and (177)Lu is a form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors (NET). AIM: The aim of the study was to evaluate clinical results and long-term side effects of tandem (90)Y /(177)Lu-DOTATATE therapy in patients with NET. Additionally, we evaluated clinical results with reference to the primary site. MATERIALS AND METHODS: 59 patients with disseminated NET were included in the study prospectively...
March 18, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28293026/therapy-the-role-of-liquid-biopsies-to-manage-and-predict-prrt-for-nets
#8
Mark Kidd, Irvin M Modlin
No abstract text is available yet for this article.
March 15, 2017: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28263217/peptide-receptor-radionuclide-therapy-with-177-lu-octreotate-in-patients-with-somatostatin-receptor-expressing-neuroendocrine-tumors-six-years-assessment
#9
Mohammadali Hamiditabar, Muzammil Ali, Joseph Roys, Edward M Wolin, Thomas M OʼDorisio, David Ranganathan, Izabela Tworowska, Jonathan R Strosberg, Ebrahim S Delpassand
OBJECTIVES: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues is a promising treatment for patients with inoperable, well to moderately differentiated metastatic neuroendocrine tumors (NETs). In continuation of our novel study with the radionuclide lutetium Lu, we now present further results of Lu DOTATATE therapy in managing NETs and other somatostatin receptor-expressing tumors in a larger and more diverse patient group. PATIENTS AND METHODS: One hundred forty-four consecutive patients (85 men and 59 women; age range, 11-87 years; mean age, 58...
March 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28246882/safety-of-multiple-repeated-cycles-of-177-lu-octreotate-in-patients-with-recurrent-neuroendocrine-tumour
#10
Anna Yordanova, Karin Mayer, Peter Brossart, Maria A Gonzalez-Carmona, Christian P Strassburg, Markus Essler, Hojjat Ahmadzadehfar
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). Still unclear is how many cycles of (177)Lu-octreotate can be repeated while maintaining an acceptable toxicity profile. The purpose of this study was to assess the safety of repeated PRRT in patients with recurrent NET. METHODS: We retrospectively evaluated data from 15 patients treated with repeated PRRT between 2004 and 2015...
March 1, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28220446/radionuclide-therapy-for-neuroendocrine-tumors
#11
REVIEW
Mauro Cives, Jonathan Strosberg
Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin receptors. The two radiopeptides most commonly used for PRRT, (90)Y-DOTATOC and (177)Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial has compared (177)Lu-DOTATATE versus high-dose octreotide LAR in patients with progressive, metastatic midgut NETs, demonstrating exceptional tolerability and efficacy...
February 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28217023/metabolic-bone-disease-in-the-context-of-metastatic-neuroendocrine-tumor-differentiation-from-skeletal-metastasis-the-molecular-pet-ct-imaging-features-and-exploring-the-possible-etiopathologies-including-parathyroid-adenoma-men1-and-paraneoplastic-humoral
#12
Rohit Ranade, Sandip Basu
Three cases of metabolic bone disease in the setting of metastatic neuroendocrine tumor (NET) are illustrated with associated etiopathologies.  One of these cases harbored mixed lesions in the form of vertebral metastasis (biopsy proven) while the other skeletal lesions were caused due to metabolic bone disease related to multiple parathyroid adenomas. While the metastatic lesion was positive on 68Ga-DOTATATE positron emission tomography-computed tomography (PET-CT), the lesions of metabolic bone disease were negative and the 18F-fluoride PET-CT demonstrated the features of metabolic bone scan...
January 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28203088/peptide-receptor-radionuclide-therapy-in-the-management-of-gastrointestinal-neuroendocrine-tumors-efficacy-profile-safety-and-quality-of-life
#13
REVIEW
Stefano Severi, Ilaria Grassi, Silvia Nicolini, Maddalena Sansovini, Alberto Bongiovanni, Giovanni Paganelli
Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitting radioisotope. The compounds differ from each other in terms of their energetic features (due to the radionuclide) and peptide receptor affinity (due to the analog) but share the common characteristic of binding specific membrane somatostatin receptors that are (generally) overexpressed in neuroendocrine neoplasms (NENs) and their metastases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28178157/the-prognostic-influence-of-the-proliferative-discordance-in-metastatic-pancreatic-neuroendocrine-carcinoma-revealed-by-peptide-receptor-radionuclide-therapy-case-report-and-review-of-literature
#14
Nathanaëlle Montanier, Juliette Joubert-Zakeyh, Caroline Pétorin, Pierre François Montoriol, Salwan Maqdasy, Antony Kelly
RATIONALE: Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2). Chemotherapy is the mainstay in the management of grade 3 (G3) unresectable pancreatic neuroendocrine carcinoma (pNEC). To date, no study has evaluated the efficacy of PRRT in such tumors...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28166370/peptide-receptor-radionuclide-treatment-and-131-i-mibg-in-the-management-of-patients-with-metastatic-progressive-phaeochromocytomas-and-paragangliomas
#15
Konstantinos Nastos, Vincent T F Cheung, Christos Toumpanakis, Shaunak Navalkissoor, Anne-Marie Quigley, Martyn Caplin, Bernard Khoo
BACKGROUND AND OBJECTIVES: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGLs) and phaeochromocytomas (PCCs). The aim of the present study is to retrospectively compare the therapeutic outcomes of these modalities in patients with progressive/metastatic PCCs and PGLs. METHODS: Patients with progressive/metastatic PGLs and PCCs that were subjected to radionuclide treatment in our department were retrieved from our department's database for the period 1998-2013...
March 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28154019/mib-1-index-stratified-assessment-of-dual-tracer-pet-ct-with-68-ga-dotatate-and-18-f-fdg-and-multimodality-anatomic-imaging-in-metastatic-neuroendocrine-tumors-of-unknown-primary-in-a-prrt-workup-setting
#16
Nikita Sampathirao, Sandip Basu
Our aim was to comparatively assess dual-tracer PET/CT ((68)Ga-DOTATATE and (18)F-FDG) and multimodality anatomic imaging in studying metastatic neuroendocrine tumors (NETs) of unknown primary (CUP-NETs) scheduled for peptide receptor radionuclide therapy for divergence of tracer uptake on dual-tracer PET/CT, detection of primary, and overall lesion detection vis-a-vis tumor proliferation index (MIB-1/Ki-67). Methods: Fifty-one patients with CUP-NETs (25 men, 26 women; age, 22-74 y), histopathologically proven and thoroughly investigated with conventional imaging modalities (ultrasonography, CT/contrast-enhanced CT, MRI, and endoscopic ultrasound, wherever applicable), were retrospectively analyzed...
March 2017: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/28138688/twins-in-spirit-part-iv-177-lu-%C3%A2-high%C3%A2-affinity-dotatate-a-promising-new-tracer-for-peptide-receptor-radiotherapy
#17
Claudia Brogsitter, Holger Hartmann, Gerd Wunderlich, Margret Schottelius, Hans-Jürgen Wester, Jörg Kotzerke
AIM: Besides the use of somatostatin analogues, small molecules like sunitinib and everolimus as well as conventional chemotherapy, peptide receptor radiotherapy (PRRT) using radiolabelled somatostatin analogues has gained an important role in the treatment of inoperable, metastasized neuroendocrine tumours (NET). There are various radiotracers in use. Based on our experience with the PET tracer [(68)Ga]DOTA-3-iodo-Tyr(3)-octreotate ([(68)Ga]HA-DOTATATE), a DOTATATE derivative with an increased binding affinity to hsst5, the current retrospective analysis is exploring the therapeutic potential of [(177)Lu]HA-DOTATATE...
February 14, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/27928786/-implementation-of-multidisciplinary-team-in-the-diagnosis-and-treatment-of-gastroenteropancreatic-neuroendocrine-neoplasm
#18
Panpan Zhang, Lin Shen
Multidisciplinary team(MDT) has been considered as the best practice in the treatment planning and care for patients with cancer around the world. With the increased range and number of specialists involved, multidisciplinary coordination and communication have been enhanced, and the efficiency and quality of diagnosis and treatment of cancer have been improved. Neuroendocrine neoplasm (NEN) is a heterogeneous group of tumors originating from neuroendocrine cells located throughout the body, most of which is gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN)...
November 25, 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27922860/the-impact-of-radiological-response-to-peptide-receptor-radionuclide-therapy-on-overall-survival-in-patients-with-metastatic-midgut-neuroendocrine-tumors
#19
Mehmet Yalchin, Amelia Oliveira, Eleni Theocharidou, Deborah Pencharz, Shaunak Navalkissoor, Ann-Marie Quigley, Martin Walker, Martyn Caplin, Christos Toumpanakis
PURPOSE OF THE REPORT: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced neuroendocrine tumors (NET); however, long-term survival data are scarce. The aim of this study is to determine long-term survival in patients with metastatic midgut NET, according to response to PRRT. PATIENTS AND METHODS: One hundred thirty-three consecutive patients with progressive metastatic midgut NET underwent PRRT. Response at 1 year post PRRT was classified as partial response, stable disease, disease progression, or death...
March 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27904799/a-clinical-guide-to-the-assessment-and-treatment-of-breathing-pattern-disorders-in-the-physically-active-part-2-a-case-series
#20
Jena Hansen-Honeycutt, Erin B Chapman, Alan Nasypany, Russell T Baker, Jim May
INTRODUCTION: Breathing pattern disorders (BPDs) are characterized by persistent, suboptimal breathing strategies that may result in additional musculoskeletal pain and/or dysfunction. The purpose of this case series was to examine the effects of Primal Reflex Release Technique (PRRT) and breathing exercise interventions in physically active individuals that presented with a primary complaint of musculoskeletal pain, a BPD, and startle reflexes. SUBJECTS: The assessment techniques described in Part 1 of this series were used to identify three student athletes (aged 16-22) who presented with musculoskeletal pain of the low back, mid back, and knee, BPDs, and startle reflexes...
December 2016: International Journal of Sports Physical Therapy
keyword
keyword
83339
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"